Correction
In the article by Egan et al, “2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals,” which published online on August 19, 2016, and appeared in the August 2016 issue of the journal (J Am Heart Assoc. 2016;5:e003558 doi: 10.1161/JAHA.116.003558), an incorrect version of Figure 2 was published.
Figure 2.
Absolute Risk Reduction (ARR, % [top panel]), number needed‐to‐treat (NNT [middle panel]) for 10 years, and atherosclerotic cardiovascular disease (ASCVD) events prevented over 10 years (bottom panel) are depicted for adults with and without diabetes mellitus and ASCVD 10 ≥7.5%. The data points reflect ARR, NNT, and ASCVD events prevented as the proportion of individuals on moderate‐dose (MD) and high‐dose (HD) statins varies from 0% to 100% in 25% increments.
The published Figure 2 reflected the sensitivity analysis for various percentages reduction in LDL‐cholesterol with moderate‐ and high‐intensity statin therapy rather than the revised sensitivity analysis with different percentages of patients on moderate‐ and high‐intensity statins, as intended by the authors. The legend to Figure 2 read as follows:
Figure 2. Absolute risk reduction (ARR) in 10‐year risk for atherosclerotic cardiovascular disease (ASCVD)10 and number needed‐to‐treat (NNT) to prevent an ASCVD event are depicted for adults with and without diabetes mellitus and with ASCVD10 ≥7.5%. The data points reflect changes in ARR and NNT as the proportion of individuals taking moderate‐dose (MD) and high‐dose (HD) statins varies from 0% to 100% in 25% increments.
Figure 2 has been replaced with a corrected figure, and the legend to Figure 2 has been corrected.
The authors regret the error.
The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/5/8/e003558.full
J Am Heart Assoc. 2016;5:e002124 doi: 10.1161/JAHA.116.002124.